Jan
4

MCMC has acquired CompPartners

In a deal just done, workers comp managed care firm MCMC will be/has acquired California-based CompPartners.  The deal gives MCMC a greater footprint in the nation’s largest workers’ comp market, and adds significant strength in physician peer review along with CompPartners’ MPN network.

CompPartners’ clients include the state fund of California (SCIF). Bunch and Associates, Liberty, AIG, TriStar, and Harbor America.  As MCMC does not have much business with most of these, there’s every indication that CP staff will remain in place to serve existing customers and find cross-selling opportunities to deliver MCMC services to Comppartners’ present customer base.

Word from an informed source close to the deal is the two companies will continue to operate separately although cross-selling will be key to leveraging the deal.  The transaction, which closed before the end of the year, was a stock deal which makes a great deal of sense for all parties.

Finally, adding significant strength in California has long been a need for MCMC.  Acquiring CompPartners gives them a staff with long experience and a solid track record in the Golden State, along with a robust client list, certified/licensed product/service offerings, and all the benefits of taking over a going concern.

The net – Smart deal for both parties, and good news for their clients and owners.


Jan
3

Quick News Briefs for work comp folks

First up, another round of applause for the good folks at the Accident Fund  – their use of predictive analytics combined with medical management expertise to identify and intervene in workers comp claims with potentially inappropriate opioid usage was one of the top ten innovations in the entire insurance industry – group, life, property casualty, and reinsurance. (Accident Fund is an HSA consulting client).  Kudos to Jeffrey Austin White, Pat Walsh, Paul Kauffman, and their colleagues and co-workers.  This is EXACTLY the kind of project work comp carriers should – and can – be doing to attack this issue.

A reviewer for Best’s Review put it this way:

“the idea of using predictive analytics informed by medical subject matter experts with workers compensation claims management software in order to identify – and pro-actively facilitate early intervention when appropriate – cases where injured workers might be reliant on opioids…strikes me as particularly innovative…”

In a related bit of news, makers of so-called “tamper-resistant” opioids are losing a battle to prevent generic versions from hitting the market – this means workers’ comp payers’ drug costs will be lower as they won’t have to pay the premium price charged for branded drugs.  While manufacturers Endo and Purdue claim their new formulations are primarily designed to increase patient safety, the timing of their introduction – just as their current brand drugs’ patent protection expires – indicates profits may be the primary motive…

A great summary of the components of the fiscal cliff deal was put together by the National Priorities project.  In chart form, it tells what happened, what it means, and what’s next.  Read it during lunch…

One of the key components of the deal was the extension of current Medicare reimbursement for physicians.  Under SGR, reimbursement was slated to drop 26.5%, however the deal extends current rates for the rest of the year.  As most WC doc fee schedules are tied indirectly to Medicare, in some states this has a direct impact on WC; in all it as an indirect impact as a cut in reimbursement would likely have led to even more cost shifting to comp…

Of note, there are several deals still working in the comp services/managed care arena.  Now that the cliff deal is done, and the deadline for changes in the capital gains rate has passed, we’ll likely see a bit of a slowdown in transactions.  However, even though the capital gains rate is increasing from 15 to 20 percent, there will still be a lot of transactions in 2014, albeit not at the feverish pace we saw at the end of last year.

Finally, with Michigan and Illinois joining the increasing number of states restricting upcharging for repackaged drugs dispensed by physicians, some payers are starting to see price increases for repackaged drugs in Florida, Maryland, and other states where the sky’s the limit.

Tomorrow, predictions for 2013.  Hoping to do better than 65%…


Jan
2

So, how’d those predictions for 2012 turn out?

It’s time to see how my predictions for 2012 turned out, and a final warning that the annual April 1 post is less than three months away…

So here are they are…and here’s how it went…

1. Health reform will impact workers comp…network discounts will diminish…Network options will change.

DING DING.  While the impact of reform is yet to be readily apparent, the data points are trending in that direction. Among the payers I work with and from other data I’ve seen, discounts have eroded and facility costs increased as negotiating leverage has shifted.  And, with the notable exception of Aetna, there was almost no movement among major health plans – including Anthem – to start or beef up their work comp offerings.

2. M&A in comp is going to accelerate.

Well, that was easy.  With deals ranging from Coventry’s sale to Aetna to ScripNet’s to Healthcare Solutions, plus TMS to MSC, MSC to Odyssey, the Align/Smartcomp merger, sale of Injured Workers Pharmacy, plus several others, 2012 may well have been the busiest year ever in this tiny little niche.

3. Comp rates will go up.

True that.  Most states  – from California to Florida to Connecticut to Maine – saw rate increases, with rates level in few e.g. NY (hmmm, perhaps due to political reasons?) and lower in the even fewer states with significant reforms (IL).

4. Attacking opioid addiction and dependency will hit the top of many payers’, regulators’, and employers’ agendas.

Halla-freakin’-luya.  With PBMs’ opioid programs getting major traction with many clients (at last); IAIABC and AIA developing policies/model language on the topic; an entire, and quite well-attended, track at NWCDC devoted to the issue; major progress in Texas and Washington; a first-ever conference on the subject attracting over 600 attendees (Operation UNITE), and every pundit and opinionator now on the band wagon, you couldn’t swing the proverbial hat without smacking into an opioid program/conversation/report.

We need more.

5. Now that Illinois is starting to approve Preferred Provider Programs, there will be lots of interest followed by disappointment that they really don’t do much to control over-utilization.

Premature at best.  The approval process has been somewhat slow, perhaps due to what appears to be a very methodical approach to writing the regs.  Jury’s out, till we have some actual PPP performance.

6. As work comp premiums begin to rise, we’re going to see a renewed interest in loss control, risk management, and medical management.

A guarded yes, with particular focus on opioids (see above), utilization management (see California), networks and specialty managed care.  To be entirely accurate – which is a noble if unattainable goal – my sense is a lot of the attention focused on specialty managed care is due to the dollars flooding into the space from private equity firms, a flow that has gotten a LOT of attention from payers.

Not much news about more work on loss control or risk management, so it may well be that this prognostication was premature.  As this would make the prediction only one-third accurate, I’ll count this a ‘no”.

7. The physician dispensing cost control bill currently pending in Florida will pass.

No DAMN IT.  Despite the dedicated, noble and diligent efforts of Senator Alan Hays (the most straight-forward and direct elected official I’ve ever had the pleasure to meet), the bill was never brought to a vote in the Senate, as then-Senate-President Mike Haridopolous refused to allow it to be brought to the floor.  If you’re wondering if the $3.4 million spent on lobbying and contributions by the physician dispensing industry had something to do with Haridopolous’ position, I’d say you’re pretty damn naive to “wonder”.

That said, there was GREAT news in Illinois and most recently Michigan, where the profiteering plunderers who suck money out of employers’/taxpayers pockets were dealt severe setbacks when regulations preventing upcharging for repackaged drugs.

8. More payers will diversify their provider network partners.

Done.  There are more payers working with more networks than before, and more bill review companies are offering more generalist and specialty networks than ever.

9. York Claims will finish the year well on its way to becoming a top-tier TPA.

It is.  With the acquisition of JI Companies and organic growth to boot, they’ve had a pretty good year in terms of revenue growth  York’s programs, staff, and capabilities – as well as the approach they take to medical management – are as good as anyone’s.

10. Oklahoma will eliminate the requirement that all employers have workers comp insurance.

Well, blew that one too.

So, here’s the score.

3 – NOs

6 – YESes

1 –  NOT YET BUT ON THE WAY.

If this was baseball, I’d be earning gazillions…alas it isn’t so.


Dec
21

What’s new with CorVel, part 2

Yesterday’s post on CorVel was cut short by the demands of real work; here’s the rest.

Financially, CorVel has had a very mediocre year.  Their most recent quarter saw revenues stay pretty much flat, while earnings dropped 10 cents a share from 68 cents the previous quarter; the last six months saw a decline of the same magnitude. Revenues increased less than a million dollars for the latest quarter, while “cost of revenues: was up about $4 million.  The company attributed that increase to the higher cost of running their TPA operations, which are more labor-intensive than managed care ops, and higher costs for drugs.

The company’s stock price has remained surprisingly high, perhaps due in part to their ongoing stock buyback program.

With a P/E ratio currently above 20, that strategy seems to be working well.

Their latest push appears to be in pharmacy, where they’ve been touting MedCheck’s ability to control costs more effectively than PBMs (disclosure – I work with a number of PBMs thru CompPharma).

Here’s how their most recent press release put it:

CorVel is uniquely positioned in the marketplace to more effectively manage pharmacy costs due to the Company’s integration with its bill review solution. MedCheck?, the Company’s medical bill review software, captures all prescription out of network transactions such as the rising occurrence of physician dispensing. These transactions are generally not managed via pharmacy benefit management (PBM) programs, which traditionally only track point of sale (POS) prescription purchases.

Sounds good, except it’s wrong.

In fact, most PBMs do capture prescriptions from third party billers, mail order, paper bills; a majority see bills from physicians as well (over half, according to the latest data on the subject).

Notably, CorVel’s “PBM” uses one of the huge group health/Medicare PBMs’ pharmacy contracts.  While this can drive great discounts, network penetration (the percentage of scripts that actually go thru the network) is often an issue. (basing this on data I’ve seen from several payers that have used different PBMs).  Thus, they can deliver great rates but for a relatively smaller number of scripts.

Finally, management.

Founder Gordon Clemons Sr is listed as CEO, a position he has held since Dan Starck’s departure earlier this year. Clemons’ son, Victor Gordon Jr., was rumored to be tagged to take over for Senior, however that apparently didn’t work out; Jr. resigned a couple months ago to “pursue personal interests.”

So, what does the future hold for CorVel?

I’ll stay away from stock prices; my portfolio (which doesn’t include CorVel) is ample evidence of my complete inability to pick stocks.

The company is decentralized, with regional execs essentially running regional businesses.  There’s a good deal of autonomy, and some offices are quite good while others are not. The challenge comes in working with national payers who want consistency; that’s tough for any decentralized operation.  Their sweet spot is mid-tier and smaller regional payers, although they do work with at least one national insurer.

The foray into the TPA world has reportedly had mixed results; CorVel’s been able to add business, while losing managed care business from TPAs that now consider – rightly so – CorVel to be a competitor.

As the work comp insurance market hardens, there will be more opportunities for TPAs as employers seek lower costs from self-insurance.  However, buyers are getting more savvy as well, and CorVel’s going to have to be aware of this dynamic; employers are increasingly aware that TPAs make up for low claims fees by increasing revenues from managed care services.   

 


Dec
20

What’s up with CorVel?

It’s been a while since we last looked in to see what’s going on at the managed care company/TPA.  Back in May, CEO Dan Starck left to go back to his previous employer, leaving a hole at the top.

Senior staff welcomed former CEO Gordon Clemons senior back, but Gordon junior was rumored to be in the running for the top slot.  Word is senior management wasn’t all that excited. More to come…

Financials for the most recent quarter are not great: revenues are essentially flat and earnings down 10 cents per share from 68 cents the prior quarter.

CorVel has been operating as a TPA and managed care firm for several years now.  While I don’t have access to any data on their TPA performance, there is data available on their managed care results.

Fortunately, the good folk at Texas Division of Workers’ Comp provide an evaluation of the networks operating in the Lone Star State; CorVel’s is included. The news is not so good.  CorVel’s network performance in Texas is, well, poor relative to the competition.  With average medical cost per claim almost 10 percent higher than the next most costly HCN, CorVel’s customers have the highest medical cost per claim of any HCN in the study. Other data points of note:

  • 37 percent of injured employees reported problems accessing care, second lowest among all HCNs in the study.
  • 12 percent of injured employees reported they had not returned to work, second worst in the study.

It is possible CorVel’s client base has greater risks and more severe injuries.  The 2011 report indicated CorVel had the highest rate of lost time claims of all networks – a whopping 42% of all claims were lost time

I was talking to an insurance company claims exec about CorVel; this was her/his take: “We have always been concerned about them from an ALAE [allocated loss adjustment expense] standpoint.  They only started the TPA business because the other TPAs were taking all their other bill review and case management business away.

Unfortunately, they are not alone when it comes to TPAs who put greater emphasis on ALAE billing than claims handling.  It’s a plague of the industry right now.”

As I’ve noted in the past, this is partially the responsibility of employers.  They’ve been able to beat up TPAs for ever-lower administrative fees to the point that some TPAs were losing money on claims handling.  As TPAs seem to remain solvent, many have looked to increase charges for managed care services, and perhaps CorVel is one that has followed this route.

 


Dec
19

Work comp hospital costs on the rise

Workers comp payers around the country are seeing their bills – and payments – for inpatient and outpatient services increase significantly faster than other costs.

And all indications are those increases are going to…increase.

The latest WCRI reports (kudos to Rick Victor et al for getting ever-more current data into their studies) show facility costs are up substantially in several states.  Indiana’s facility costs were substantially higher than WCRI’s median states, driven by prices.  As Indiana doesn’t have a fee schedule for facilities, hospitals can jack up prices whenever they want – and they are.

WCRI reported overall hospital inpatient payments per stay increased 12% per year from 04/05 to 09/10; anecdotal information from HSA consulting clients indicate Indiana hospital prices are up significantly this year.

At that rate, your costs will double every six years.

And that’s the best case scenario.

What’s behind my pessimistic forecast is the news that hospitals will likely take a big hit in the fiscal cliff deal.  Medicare is going to get cut, and policymakers are focusing on facilities rather than physicians as the primary target for reductions in reimbursement.

What does this mean for you?

When – not if – those cuts are announced, we can expect facility costs to increase. In states like Indiana where there is no fee schedule, those increases will be driven by a combinaton of higher prices and more services per episode.

In fee schedule states, watch for significant increases in utilization – more and higher-intensity services per stay.

For a detailed view into workers’ comp outpatient costs and cost drivers, watch WCRI’s webinar on the subject.


Dec
18

The latest on compounding pharmacies

Looks like Congress is pressing forward on efforts to clean up the regulatory gaps implicated in the New England Compounding Center tragedy.

Rita Ayers, CEO of Tower MSA Partners, has been tracking the US Senate’s work on the issue; the latest is Tom Harkin, (D IA) Chair of the HELP Committee sent a letter to the Boards of Pharmacy in all fifty states requesting information on their oversight of compounding pharmacies and their efforts to follow up on the NECC disaster.  The letter, which went out in mid-November, requested responses by December 7 of this year.

No word on what Harkin et al heard back, or if the Pharmacy Boards did respond on schedule.

What we do know is this.

  • Oversight of compounding pharmacies is quite a bit looser than pharmaceutical manufacturers, and the regulatory compliance process is much less onerous for compounders
  • Compounds are supposed to be developed/made up for individual patients or a relatively small number of patients.
  • Some compounders look a lot like manufacturers, as they make thousands of doses – just like manufacturers
  • Some states have a very light regulatory “touch” while others are pretty tough.

What does this mean for you?

A warning for patients, providers, and pharmacists alike, and evidence that – in some instances – we need more and better regulation, not less.

 


Dec
14

Is workers’ comp over?

Should it be?  Has it become such an unwieldy morass of conflicting regulations, an all-too-soft target for profiteers and plunderers that it is largely dysfunctional?

If so, we may well see other states follow Texas’ lead and allow employers to opt out of workers’ comp.

Friend and colleague Peter Rousmaniere has authored a comprehensive study of the subject, one regulators and legislators would be well-advised to put on their holiday reading list.


Dec
11

Comp medical costs on the rise

The latest report from WCRI shows medical costs in Indiana have been rising rapidly over the last few years, driven by facility cost increases.  This comes as no surprise, as facilities’ increasing leverage and ability to raise prices has been affecting comp in many states.

This comes on the heels of a similar report on Virginia and news of a significant rate jump in New Jersey, in large part due to increased medical trend.

Rates are up in the Sunshine State too, and yes, higher medical costs – facility and repackaged drugs – are the driver.

Over the last few years, medical inflation, as reported by NCCI has been pretty much under control.  It certainly looks as if those days are over.

What does this mean for you?

Time to dust off those medical management programs – and update them as well.  Because what worked back in the day will likely not work now.  If it did, you wouldn’t see these cost increases.

 

 


Dec
6

Manufacturing’s coming back

Update – And with it will come higher workers comp premium revenue.

The most comprehensive report on the resurgence of American manufacturing is in this month’s Atlantic magazine.  (Over at WorkersCompInsider, Julie Ferguson beat me to the punch on this piece – Julie has quite a bit of insight into the trend and other reports as well…

Among the many companies bringing jobs back from China, Mexico, and southeast Asia are GE (appliances), .

Manufacturing jobs are returning to America from overseas for multiple reasons (paraphrased from Atlantic and other sources) –

  • Transporting stuff in oil-powered ships is much more expensive these days; oil prices are three times higher than they were 2000
  • The natural-gas boom in the U.S. has greatly reduced US manufacturing’s energy costs; costs are much higher in Asia
  • Wages in China are rising 18 percent a year, and by 2014 wages around Shanghai will be 60% of those in Alabama.
  • American unions are changing and adapting, getting more flexible and working much more closely with management to drive “lean manufacturing.”
  • U.S. labor is getting more and more productive, reducing the percentage of manufacturing costs consumed by labor.
There’s also something much more fundamental going on here.  Manufacturers are finding out the truism that lower labor costs “win” reflects a superficial understanding of costs, and in many cases is just wrong.
Moving manufacturing overseas removed manufacturing expertise as well.  And while that didn’t seem to be much of an issue fifteen years ago, it turns out that when the people designing, building, selling, and using the appliances/machines/machine tools are in the same building or area, they can quickly figure out how to reduce materials cost, dramatically increase build quality, and streamline manufacturing, further reducing cost.  Moreover, the cycle time can be drastically shortened as well.
That’s becoming increasingly important as products’ life cycles have dropped from seven to two years.
What does this mean for you?
While manufacturing is returning, the working conditions, safety issues, injury types and risk management of all of the above won’t be the same.  There’s much more automation, much less “manual” labor, and different risks than there were back in the day.
Be ready.